TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04612738

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hello (serious game)
Description: Commercially available, 'Hello' 32 is a serious game that consists of 32 questions prompting players to share their values, goals, and beliefs about end-of-life issues. The creators developed the questions following interviews with palliative care clinicians, hospice nurses, and funeral directors, and then revised them through a series focus groups with \>100 patients/caregivers from diverse backgrounds.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Conversation Project (CP) Starter Kit
Description: The CP Starter Kit is one of the most widely promoted and disseminated ACP tools nationwide, is available for free online, and does not require a healthcare professional for use. Like 'Hello', it is intended to help individuals have end-of-life conversations with loved ones. The 11-page workbook has open- ended prompts to consider one's values and preferences for end-of-life care, who to talk with about one's wishes, and suggestions on how to do so. It also prompts participants to rank priorities on a 5-point scale (e.g., What are your concerns about treatment? 1= I'm worried I won't get enough care, 5= I'm worried I'll get overly aggressive care). The CP website provides resources for running a community event using the 'CP Starter Kit', including a 23-page manual, Coaching the Conversation- A Guide to Facilitating Conversation Groups, with details on hosting a community-based program.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Table Topics (general conversation game)
Description: Table topics is a popular, commercially available conversation starter game that consists of question cards to prompt conversations (e.g., 'What do you love about your hometown?').
Study: NCT06128902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tele health
Description: home based exercise and telenursing
Study: NCT05508698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precommitment Nudge
Description: Ask participants to commit to a decision about getting a flu shot

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salience
Description: Additional text and icon in the flu shot alert makes the pre-visit questionnaire response salient to the clinician, which could facilitate action or further discussion with the patient
Study: NCT06246240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum with vitamin C
Description: Will chew vitamin C gum as soon as nausea begins
Study: NCT05103020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks
Description: Bevacizumab : 5mg/kg IV over 30min, day 1 or Cetuximab : 500 mg/m2 IV over 2-hr, day 1 Oxaliplatin : HAI 100mg/m2 IV over 2-hr, day 1 Leucovorin : 400mg/m2 IV over 2-hr, day 1 5-Fluorouracil : 2400mg/m2 infusion for 46-h Irinotecan : 180mg/m2 IV over 1.5-hr, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks
Description: Bevacizumab : 5mg/kg IV over 30min, day 1 or Cetuximab : 500 mg/m2 IV over 2-hr, day 1 Irinotecan : 180mg/m2 IV over 1.5-hr, day 1 Leucovorin : 400mg/m2, IV over 2-hr, day 1 5-Fluorouracil : 400mg/m2 IV bolus, day 1 5-Fluorouracil : 2400mg/m2, infusion for 46-h
Study: NCT05812157

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Daily dietary supplementation with Fibruline
Description: Supplementation with 12 grams per day of Fibruline reconstituted with 60mL of water, once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily dietary supplementation with Fibruline
Description: Supplementation with 12 grams per day of Fibruline reconstituted with 60mL of water, once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-IL-17 therapy
Description: Patients in both groups will be on anti-IL-17 therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IL-17 therapy
Description: Patients in both groups will be on anti-IL-17 therapy
Study: NCT04195308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TBS-DLPFC
Description: Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS-DLPFC
Description: The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Open label TBS-DLPFC
Description: Patients will have the option of receiving active, open label aTBS treatment following sham.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device.
Study: NCT06193252

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Increase of physical activity volume and intensity with the use of a motivational smartphone application
Description: A motivational smartphone application will be available for all participants using their own smartphone: the Slow-SPEED app. The Slow-SPEED app will motivate participants to increase the volume and intensity of their physical activity in daily life over a long period of time (2 years) based on their own baseline levels. Different treatment arms will receive different physical activity goals. The app offers participants feedback and support, that will stimulate them to reach their individual physical activity goal (i.e. incremental relative increase of step count and minutes exerting ≥ 64% of maximum heart rate reflecting MVPA relative to baseline level.).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase of physical activity volume and intensity with the use of a motivational smartphone application
Description: A motivational smartphone application will be available for all participants using their own smartphone: the Slow-SPEED app. The Slow-SPEED app will motivate participants to increase the volume and intensity of their physical activity in daily life over a long period of time (2 years) based on their own baseline levels. Different treatment arms will receive different physical activity goals. The app offers participants feedback and support, that will stimulate them to reach their individual physical activity goal (i.e. incremental relative increase of step count and minutes exerting ≥ 64% of maximum heart rate reflecting MVPA relative to baseline level.).
Study: NCT04895722

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 400 mg or 200 mg pembrolizumab administered via IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg or 200 mg pembrolizumab administered via IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) fixed-dose combination (FDC) administered via IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Favezelimab
Description: Co-formulated pembrolizumab/favezelimab (200 mg/800 mg) FDC administered via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab
Description: Co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) FDC administered via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: 800 mg MK-4830 administered via IV infusion
Study: NCT06523673

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: The dose of radiation therapy is determined by the radiologist based on the clinical parameters of the lesion, including tumor size and location. In most cases, radiotherapy fractionation regimens range from 27-30 Gy/3 Fractions or 30-50 Gy/5 Fractions, and appropriate radiotherapy doses covering 27-70 Gy/3-10 Fractions can also be selected by the radiologist based on radiation limitations of neighboring endangered organs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: second-line systemic therapy
Description: a second-line docetaxel/albumin-bound paclitaxel-based systemic therapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: second-line systemic therapy
Description: a second-line docetaxel/albumin-bound paclitaxel-based systemic therapy regimen
Study: NCT06167837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide Sulfone
Description: Metoclopramide 10mg+NSS 10 ml IV 30-60 minutes before EGD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 10 mL Injection
Description: Normal saline 10 ml IV 30-60 minutes before EGD
Study: NCT06353984

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Minimeal product
Description: Intervention product consisting of bioprocessed oats and chickpeas

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference product
Description: Reference product mimicking available soups and fruit drinks
Study: NCT05416580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA (Ursodeoxycholic acid)
Description: UDCA is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin therapy is administered in the recommended dose in patients with type 2 diabetes mellitus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin therapy is administered in the recommended dose in patients with type 2 diabetes mellitus.
Study: NCT04496726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacran and Sapnov P quillaja
Description: Cranberry (450 mg) and quillaja (50 mg) capsules taken orally twice daily (morning and evening) for a total daily dose of 900 mg cranberry and 100 mg quillaja for 14 days. Nitrofurantoin 100 mg taken orally twice daily for five days as a rescue medication if symptoms do not subside.
Study: NCT04369560

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: 60-cm wide bore 3T scanner (Siemens AG, Erlangen, Germany) with a 32-channel pelvic phased-array coil placed over the bladder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol intravesical administration (4mM)
Description: A paramagnetic macrocyclic gadolinium-based contrast agent administered intravenously for use in magnetic resonance imaging. Contrast-enhancement is a result of the neutral complex of gadolinium and dihydroxy-hydroxymethylpropyl- tetraazacyclododecane-triacetic acid (butrol).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol intravesical administration (5 mM)
Description: An iron preparation (Fe3O4) approved for intravenous treatment of anemia in the setting of renal failure, comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution.
Study: NCT06419322

Intervention type: OTHER
Group type: OTHER
Intervention: Optimized rehabilitation program
Description: Consisting of: goal-oriented rehabilitation, hands on physiotherapy sessions and home use of SMA approved rehabilitation device.
Study: NCT05358821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: SAGE-718 oral softgel lipid capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-718-matching oral capsules
Study: NCT05356260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: URincontrol4men
Description: The intervention is built as an app

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.
Study: NCT06338319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Book-Sharing for Toddlers with Clefts (BOOST)
Description: BOOST is a dialogic book-sharing intervention. Topics covered include strategies to increase the frequency of shared reading, child engagement and involvement in reading, and strategies to promote language development. Handouts will be shared during the sessions (using the Zoom share screen feature) and sent to families to summarize the content. Parents will record and securely upload shared reading videos during the intervention period. The research team will send prompts for these video uploads after each intervention session. Interventionists will review these videos between sessions to identify parent strengths, application of target skills, and opportunities for improvement.
Study: NCT05875181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tFUS
Description: tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tFUS
Description: tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tFUS
Description: Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tFUS
Description: Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
Study: NCT06003803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital learning in motivational interviewing
Description: Receive digital learning in motivational interviewing for three months, once a week, 40 minutes each time
Study: NCT06479070

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: A blood sample of 20 mL (2 tubes of 10 mL) for research purposes will be collected during:~* The day of the centering scan (Visit 1);~* During treatment at Week 2 and Week 6 (+/- 1 week) (Visit 2 and 3);~* The day of the post-therapeutic visit scheduled between 3 and 5 weeks after the end of radiotherapy, whether or not associated with concomitant treatment (Visit 4);~* At each monitoring visit following radiotherapy associated or not with concomitant treatment (every 3 months for 24 months (V5 to V12 ; V12 = final visit)~* When the disease progresses before initiation of the 2nd line of treatment.
Study: NCT04769037

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B. infantis
Description: Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose identical in appearance and taste to the active supplement
Study: NCT05630183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard-of-care chemotherapy administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard-of-care chemotherapy administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Standard-of-care chemotherapy administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Standard-of-care chemotherapy administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Standard-of-care chemotherapy administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Standard-of-care chemotherapy administered intravenously.
Study: NCT05979441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EFG PH20 SC
Description: Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
Study: NCT06118411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NB-UVB (narrow-band ultraviolet B) Phototherapy
Description: NB-UVB phototherapy is a commonly used treatment modality in participants with vitiligo and can be administered in an office setting or at home 2 times per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NB-UVB (narrow-band ultraviolet B) Phototherapy
Description: NB-UVB phototherapy is a commonly used treatment modality in participants with vitiligo and can be administered in an office setting or at home 2 times per week
Study: NCT04079621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine
Description: Primaquine regimen over 7 days (0.5mg/kg/day for 7 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine
Description: Primaquine regimen over 7 days (0.5mg/kg/day for 7 days)
Study: NCT04859764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reparel knee sleeve
Description: Unlabelled thermo-active knee sleeve that improves bloodflow to knee and decreased pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid injection
Description: intraarticular knee injection of betamethasone and bupivacaine 0.5% (dose is determined by joint size)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Description: intraarticular knee injection of betamethasone and bupivacaine 0.5% (dose is determined by joint size)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo knee sleeve
Description: unlabeled compression knee sleeve
Study: NCT04764448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belcesiran
Description: Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator: Placebo Cohort 1 Administered sterile normal saline (0.9% NaCl) matching volume of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belcesiran
Description: Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belcesiran
Description: Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 96 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 96 weeks.
Study: NCT05438927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit Data Collection
Description: Participants will log food intake while sharing their data with a dietician in real time for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: Participants will receive individually tailored, biweekly nutrition counseling from a dietician via telehealth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fact G Survey
Description: Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Anxiety Disorder (GAD)-7
Description: Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire measures participants anxiety with a scale of 0=not at all, 3=Nearly everyday.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire (PHQ)-9
Description: Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire measures participants depression with a scale of 0=not at all, 3=Nearly everyday.